logo
Plus   Neg
Share
Email

Allergan, Molecular Partners Report Topline Safety Results From MAPLE Study

Allergan plc, (AGN) and Molecular Partners announced topline safety results from MAPLE, a 28 week open-label study which enrolled 123 age-related Neovascular Macular Degeneration patients and evaluated the safety of abicipar produced via a modified manufacturing process. The company said, as a result of the improvements in the manufacturing process, the incidence of intraocular inflammation or IOI, was 8.9 percent in the MAPLE study, which was lower than the rate observed in prior Phase 3 studies. Most IOI events were assessed as mild to moderate in severity, the company said. The incidence of severe IOI was 1.6 percent with one reported case of iritis and one reported case of uveitis. There were no reported cases of endophthalmitis or retinal vasculitis in the study.

"The results of this open-label study enabled us to assess improvements to the manufacturing process for abicipar. The safety profile demonstrated in MAPLE gives us confidence to proceed and scale up manufacturing," said David Nicholson, Chief Research and Development Officer, Allergan.

Allergan expects to file the abicipar Biologics License Application with the U.S. FDA in the first half of 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A new research has found unusual increase in malware, as cyber criminals find new avenues to attack. WatchGuard Technologies on Tuesday released its quarterly Internet Security Report for first quarter. The report says malware detections in the first quarter surged a massive 62% from previous quarter. The... A study has suggested that the risk of dementia is stronger in older adults on the use of anticholinergic drugs, highlighting the importance of reducing exposure to anticholinergic drugs in middle-aged and older people. Anticholinergic drugs work by blocking the action of a neurotransmitter called acetylcholine. This inhibits nerve impulses responsible for involuntary muscle movements. Norway's $1 trillion sovereign wealth fund, the world's largest, has been given the approval to invest again in retail giant Walmart Inc. and miner Rio Tinto plc, among other companies. This follows the Norway central bank's decision to revoke these companies' exclusions from the fund's investments on ethical grounds. Walmart was excluded in 2006 from the pension fund's investments.
Follow RTT